Interferência da morfologia capilar na predisposição à pediculose

Orientador: Débora do Rocio KlisiowiczMonografia (Bacharelado) - Universidade Federal do Paraná. Setor de Ciências Biológicas. Curso de Graduação em Ciências Biológica

Effects of physical exercise on functional capacity in hemodialysis patients. A systematic review

The aim of this study was to conduct a systematic review in order to evaluate the main effects of intradialytic physical exercise on different parameters of functional capacity in dialytic patients. The clinical question that guided the objective of this study was developed using the PICO method (Population, Intervention, Comparation and Outcome)." Where i) population: patients on hemodialysis; ii) intervention: physical exercise; iii) comparison: active vs sedentary patients; and iv) outcome: functional capacity. The combinations of the following keywords were used: CKD, physical exercise, exercise, physical training and hemodialysis. The selection of studies was performed using the PubMed database and only studies dating from 2011 to 2021 were selected. The search results led to 53 studies. The following steps were carefully analyzed, such as the title, abstract and the full paper description to evaluate whether they met the following inclusion criteria: i) target audience of the studies should be patients on hemodialysis; ii) outcomes that analyze different parameters of functional capacity; iii) Intervention using physical exercise; and iii) intradialytic exercise. The final results indicate that intradialytic physical exercise can cause significant changes in the evaluated outcomes of functional capacity, such as increased strength, improvement of cardiorespiratory function, and improvement of locomotor activity. It was concluded that intradialytic training protocols should be encouraged in clinical practices because they are responsible for causing beneficial changes in the functional capacity of hemodialytic patients

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

O papel da sinalização STAT-3 nas lesões renais associadas à nefropatia induzida por adriamicina

Orientador: Prof. Dr. Rafael Luiz PereiraDissertação (mestrado) - Universidade Federal do Paraná, Setor de Ciências Biológicas, Programa de Pós-Graduação em Fisiologia. Defesa : Curitiba, 29/06/2018Inclui referências: p.60-65Resumo: Dentre as glomerulopatias que conduzem à doença renal crônica (DRC) e consequente necessidade de terapia renal substitutiva (TRS), a glomeruloesclerose segmentar e focal (GESF) representa cerca de 30% dos casos. A GESF possui caráter heterogêneo, sendo caracterizada por lesão podocitária primária e perda da seletividade da barreira de filtração glomerular com consequente proteinúria, lesão tubular de caráter fibrótico e infiltrado de células inflamatórias. Além da alta morbidade e mortalidade, a doença apresenta uma taxa de recorrência pós transplante de 40%, sendo que os gastos com as TRS geram custos em torno de R$ 2 bilhões por ano. A via de sinalização STAT-3 está envolvida, dentre outras funções, na proliferação celular e inflamação e tem sido investigada como tendo papel importante na progressão de DRCs. Há alguns modelos experimentais para o estudo da GESF, no entanto, todos os modelos utilizam animais geneticamente homogêneos, o que não condiz com a realidade dos pacientes em relação à variabilidade genética. Tendo em vista a importância de estudos sobre GESF em modelos experimentais heterogêneos e a carência de dados sobre o papel da STAT- 3 no denvolvimento da patologia, este trabalho teve como objetivo avaliar o papel da via de sinalização pela STAT-3 nas lesões renais presentes na GESF e sua interferência na progressão da doença em modelo genétiticamente heterogêneo. Para tanto, foram utilizados camundongos machos Swiss, os quais tiveram GESF induzida pelo quimioterápico adriamicina (ADM) em dois protocolos distintos, sendo um utilizando a dose de 10 mg/kg e outro com dose de 25 mg/kg de ADM. Os resultados obtidos apontaram que a indução de nefropatia por ADM em animais heterogêneos é eficaz em ambas as doses estudadas, sendo que na dose de 10 mg/kg a lesão renal demora mais tempo para se estabelecer (14 dias), em relação a dose de 25 mg/kg, na qual a albuminúria já aparece nos 5 primeiros dias após a administração da droga. Também concluimos a administração de STATTIC diminui a expressão gênica e proteica de STAT-3, interferindo na via de sinalização-IL-6- STAT-3, o que tem papel importante na progressão da GESF, uma vez que a sua inibição leva á diminuição da albuminúria, fibrose tubulointersticial e necrose tubular, marcadores importantes na glomeruloesclerose segmentar e focal e intimamente ligados a progressão da doença. Palavras-chave: Glomeruloesclerose segmentar e focal. STATTIC. Proteinúria.Abstract: Among the glomerulopathies that lead to chronic kidney disease (CKD) and consequent need for renal replacement therapy (RRT), the focal segmental glomerulosclerosis (FSGS) represents about 30% of cases. FSGS has a heterogeneous character and is characterized by primary podocyte lesions associated with loss glomerular filtration barrier slectivity with consequent proteinuria, tubular lesions and infiltration of inflammatory cells. In addition to high morbidity and mortality, this disease has a post-transplant recurrence rate of 40%. The STAT-3 signaling pathway is involved, among other functions, in cell proliferation and inflammation and has been investigated in the progression of CKD. There are some experimental models for the study of FSGS, however, all these models use genetically homogeneous animals. There are some experimental models for the study of FSGS, however, all these models use genetically homogeneous animals, which does not fit the reality of the patients, which present different responses to treatments and disease progression. Considering the importance of studies on FSGS in heterogeneous experimental models and the lack of data on the role of STAT-3 in the development of pathology, this study aimed to evaluate the role of the STAT-3 signaling pathway in the present renal lesions in the FSGS and its interference in the progression of the disease in a genetically heterogeneous model. For this, Swiss male mice were used, which had FSGS induced by chemotherapeutic adriamycin (ADM) in two different protocols, one using the dose of 10 mg / kg and the other with a dose of 25 mg / kg of ADM. The results obtained indicate that the induction of ADR nephropathy in heterogeneous animals is effective in both doses studied but at a dose of 10 mg/kg renal injury takes longer to establish (14 days) than the 25 mg / kg in which albuminuria appears within the first 5 days after drug administration. We also concluded that the administration of STATTIC decreases STAT-3 gene and protein expression, interfering with the IL-6-STAT-3 signaling pathway, which plays an important role in FSGS progression, since its inhibition leads to a decrease in albuminuria, tubulointerstitial fibrosis and tubular necrosis, which are markers of this disease. Key-words: Focal segmental glomerulosclerosis. STATTIC. Proteinuria

O papel da sinalização STAT-3 nas lesões renais associadas à nefropatia induzida por adriamicina

Orientador: Prof. Dr. Rafael Luiz PereiraDissertação (mestrado) - Universidade Federal do Paraná, Setor de Ciências Biológicas, Programa de Pós-Graduação em Fisiologia. Defesa : Curitiba, 29/06/2018Inclui referências: p.60-65Resumo: Dentre as glomerulopatias que conduzem à doença renal crônica (DRC) e consequente necessidade de terapia renal substitutiva (TRS), a glomeruloesclerose segmentar e focal (GESF) representa cerca de 30% dos casos. A GESF possui caráter heterogêneo, sendo caracterizada por lesão podocitária primária e perda da seletividade da barreira de filtração glomerular com consequente proteinúria, lesão tubular de caráter fibrótico e infiltrado de células inflamatórias. Além da alta morbidade e mortalidade, a doença apresenta uma taxa de recorrência pós transplante de 40%, sendo que os gastos com as TRS geram custos em torno de R$ 2 bilhões por ano. A via de sinalização STAT-3 está envolvida, dentre outras funções, na proliferação celular e inflamação e tem sido investigada como tendo papel importante na progressão de DRCs. Há alguns modelos experimentais para o estudo da GESF, no entanto, todos os modelos utilizam animais geneticamente homogêneos, o que não condiz com a realidade dos pacientes em relação à variabilidade genética. Tendo em vista a importância de estudos sobre GESF em modelos experimentais heterogêneos e a carência de dados sobre o papel da STAT- 3 no denvolvimento da patologia, este trabalho teve como objetivo avaliar o papel da via de sinalização pela STAT-3 nas lesões renais presentes na GESF e sua interferência na progressão da doença em modelo genétiticamente heterogêneo. Para tanto, foram utilizados camundongos machos Swiss, os quais tiveram GESF induzida pelo quimioterápico adriamicina (ADM) em dois protocolos distintos, sendo um utilizando a dose de 10 mg/kg e outro com dose de 25 mg/kg de ADM. Os resultados obtidos apontaram que a indução de nefropatia por ADM em animais heterogêneos é eficaz em ambas as doses estudadas, sendo que na dose de 10 mg/kg a lesão renal demora mais tempo para se estabelecer (14 dias), em relação a dose de 25 mg/kg, na qual a albuminúria já aparece nos 5 primeiros dias após a administração da droga. Também concluimos a administração de STATTIC diminui a expressão gênica e proteica de STAT-3, interferindo na via de sinalização-IL-6- STAT-3, o que tem papel importante na progressão da GESF, uma vez que a sua inibição leva á diminuição da albuminúria, fibrose tubulointersticial e necrose tubular, marcadores importantes na glomeruloesclerose segmentar e focal e intimamente ligados a progressão da doença. Palavras-chave: Glomeruloesclerose segmentar e focal. STATTIC. Proteinúria.Abstract: Among the glomerulopathies that lead to chronic kidney disease (CKD) and consequent need for renal replacement therapy (RRT), the focal segmental glomerulosclerosis (FSGS) represents about 30% of cases. FSGS has a heterogeneous character and is characterized by primary podocyte lesions associated with loss glomerular filtration barrier slectivity with consequent proteinuria, tubular lesions and infiltration of inflammatory cells. In addition to high morbidity and mortality, this disease has a post-transplant recurrence rate of 40%. The STAT-3 signaling pathway is involved, among other functions, in cell proliferation and inflammation and has been investigated in the progression of CKD. There are some experimental models for the study of FSGS, however, all these models use genetically homogeneous animals. There are some experimental models for the study of FSGS, however, all these models use genetically homogeneous animals, which does not fit the reality of the patients, which present different responses to treatments and disease progression. Considering the importance of studies on FSGS in heterogeneous experimental models and the lack of data on the role of STAT-3 in the development of pathology, this study aimed to evaluate the role of the STAT-3 signaling pathway in the present renal lesions in the FSGS and its interference in the progression of the disease in a genetically heterogeneous model. For this, Swiss male mice were used, which had FSGS induced by chemotherapeutic adriamycin (ADM) in two different protocols, one using the dose of 10 mg / kg and the other with a dose of 25 mg / kg of ADM. The results obtained indicate that the induction of ADR nephropathy in heterogeneous animals is effective in both doses studied but at a dose of 10 mg/kg renal injury takes longer to establish (14 days) than the 25 mg / kg in which albuminuria appears within the first 5 days after drug administration. We also concluded that the administration of STATTIC decreases STAT-3 gene and protein expression, interfering with the IL-6-STAT-3 signaling pathway, which plays an important role in FSGS progression, since its inhibition leads to a decrease in albuminuria, tubulointerstitial fibrosis and tubular necrosis, which are markers of this disease. Key-words: Focal segmental glomerulosclerosis. STATTIC. Proteinuria

Problematização sobre o descarte de resíduos sólidos eletrônicos junto aos alunos de ensino fundamental e médio

Orientador: Carlos Eduardo Pileggi de SouzaTrabalho de Conclusão de Curso (Licenciatura) - Universidade Federal do Paraná. Setor de Ciências Biológicas. Curso de Graduação em Ciências Biológica

Problematização sobre o descarte de resíduos sólidos eletrônicos junto aos alunos de ensino fundamental e médio

Orientador: Carlos Eduardo Pileggi de SouzaTrabalho de Conclusão de Curso (Licenciatura) - Universidade Federal do Paraná. Setor de Ciências Biológicas. Curso de Graduação em Ciências Biológica